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ABSTRACT 
Introduction: The National Drug Policy in South Africa has achieved its objective in establishing and 
strengthening Pharmacy and Therapeutics Committees (PTCs) in all hospitals. However, little is 
known about the implementation of decisions by PTCs and the monitoring thereof. Consequently, a 
need to investigate this. Areas covered: We sought to address this via an online survey distributed to 
pharmacists working in public sector hospitals across South Africa with perceived functioning PTCs, 
with a 32.3% response rate to the survey. Expert commentary: Membership of all PTCs included a 
pharmacist, who in most cases (51.2%) held the secretariat position. Principal PTC activities were 
encouraging rational medicine use (RMU) (86.0%), pharmacovigilance (82.6%) and implementing 
standard treatment guidelines (STGs) (77.9%). Only a third (37.5%) stated that they were using 
indicators to monitor PTC performance. Where collected, indicator data were mostly used for 
providing feedback to PTCs (83.3%). Most hospitals (95.1%) implemented PTC decisions; however, 
62.0% mentioned guidelines on implementing PTC decisions did not exist in their hospital. The 
majority of respondents (65.4% and 83.8% respectively) indicated PTC decisions were evaluated and 
reviewed in their hospitals. Overall a high percentage of respondents stated the main activities of 
PTCs were to enhance RMU as well as implement STGs. However, guidelines on implementation of 
decisions by PTCs are currently lacking and most PTCs were not monitoring their performance. This 
needs to be addressed. 
 
Keywords: Pharmacy and Therapeutics Committee, Hospitals, Indicators, decision implementation, 
South Africa 
 
1. Background 
 
The establishment of Pharmacy and Therapeutics Committees (PTCs) has been advocated by the 
World Health Organization (WHO) as one of the focal models to promote rational medicine use (RMU) 
[1]. The rational use of medicines can be achieved through promoting rational prescribing, dispensing 
and use of medicines, by health care professionals, together with supporting informed and 
appropriate use of medicines by the community [2]. PTCs have worked well across countries to 
improve the quality and efficiency of prescribing [3-6], given concerns with promotional activities of 
pharmaceutical companies across countries, including low and middle-income countries [7-11].  
 
One of the goals of the South African Government is to ensure reliable supply of medicines in 
adequate quantities so that the entire population, at all times, have access to safe, high quality, cost-
effective medicines [2]. Furthermore, the rational use of medicines by prescribers, dispensers and 
consumers must be ensured [2]. For this goal to be achieved, the South African National Drug Policy 
has as one of its objectives to establish and strengthen PTCs in all hospitals (both public and private 
sector) [2, 16]. PTCs play a role by being committed to the governance of an effective medicines 
management system in order to provide equitable and reliable access to medicines and quality care, 
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while making the best use of available resources [17]. However, there have been concerns with the 
prescribing of medicines in hospitals in South Africa [12-15]. To help address concerns, and ensure 
efficient, rational and cost-effective supply and use of medicines, a system to effectively manage 
medicine use across all sectors needs to be in place, which includes a functioning PTC in hospitals 
[17].  
 
More recently, in 2015, a National Policy for the Establishment and Functioning of Pharmaceutical 
and Therapeutics Committees in South Africa was published [17]. The previous lack of a coherent 
policy for PTCs resulted in differences in the objectives and functioning of PTCs across and within the 
same level of care in South Africa [19]. However, a number of initiatives are currently under 
development including directives on the functioning of PTCs [18]. 
 
As mentioned, PTCs were developed to maximize RMU, especially in hospitals, through consideration 
of the safety and effectiveness of different medicines to treat different conditions. However, PTCs 
have evolved since their inception in terms of decision making processes around evaluating and 
promoting RMU, including physician education, auditing current prescribing, monitoring adverse drug 
reactions (ADRs), committee membership and responsibilities [3, 20, 21]. In some countries, for 
example Laos, the tasks of PTCs also included the development of medicine policies, evaluating and 
selecting medicines for the formulary list, developing, adapting and implementing standard treatment 
guidelines (STGs), assessing medicine use to identify problems, conducting interventions to improve 
medicine use against STGs, managing ADRs and rectifying medication errors [22]. Within South 
Africa in general, there are concerns with the level of reporting of ADRs and medication errors in 
hospitals, as well as lack of evidence-based decision making in formulary management, with ongoing 
activities to try and address this [18, 23-25].  
 
Objective patient and institution centered factors should ideally guide decisions taken by PTCs, 
including comparative efficacy and cost-benefit analysis of the chosen medicines [4, 18, 26].  Whilst 
PTC activities in South Africa typically include dissemination of decisions and formulary management, 
reporting of ADRs and medication errors is typically poor [12]. Furthermore, it is not totally clear how 
decisions made by most PTCs have been implemented and no indication of whether the outcomes of 
PTC decisions are being evaluated [12]. This is a concern, as evaluation provides feedback on the 
outcomes of activities such as changes in prescribing behavior, whether agreed plans and objectives 
regarding medicine use are being met and the reasons for success or failure. Evaluation should also 
provide direction for future pragmatic plans [27].  
 
Moreover, according to recommendations from the WHO, the organizational development and 
performance of the PTC should be monitored continuously and be documented using indicators, 
which are considered to be core parameters of its goals and objectives [22]. Process, impact and 
outcome indicators can be used to measure the functionality of local PTCs repeatedly, and identify 
when a PTC is effective and making an impact [28]. However to date, there has been limited 
published data regarding the performance and methods used by PTCs in South Africa to implement 
their decisions. We recently published on the activities of PTCs in public hospitals in the Gauteng 
Province in South Africa, including current concerns [12]. Consequently, the aim of this study was to 
build on this and investigate the implementation and monitoring of decisions by PTCs among public 
sector hospitals with functioning PTCs, across South Africa. Public sector hospitals were targetted for 
this research as they manage the vast majority (over 80%) of patients in South Africa [18]. 
 
2. Materials and Methods 
 
2.1 Study design and target population 
The study employed a descriptive survey design using a quantitative research approach. An 
electronic questionnaire was emailed to a pharmacist, who would normally participate in the hospital 
PTC, in public sector hospitals across South Africa. At the time of the study, there were 412 public 
sector hospitals in the nine provinces of South Africa, including district hospitals, regional hospitals, 
tertiary hospitals, central and specialized hospitals.  
 
2.2 Study population and sample 
Inclusion criteria for participation in the study were i) hospitals with a pharmacy; iii) hospitals with a 
pharmacist that could be reached by phone and by email; and iii) hospitals with a functioning PTC. 
Hospitals were first contacted via the telephone to verify eligibility for the study and obtain the email 
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address of the pertinent pharmacist to contact for the survey. At the time of the study, 8 (1.9%) of the 
412 public sector hospitals did not have a pharmacy and 35 (8.5%) did not have a functioning PTC. 
Furthermore, in the case of 90 (21.8%) hospitals, either the hospital or the pharmacist could not be 
reached at all, and in 11 (2.7%) hospitals, email invitations were undelivered. This resulted in a 
sample of 268 public sector hospitals in South Africa where the pharmacist was invited to participate 
in the study.  
 
2.3 Questionnaire design and data collection 
A questionnaire, using the electronic platform SurveyMonkey®, was developed from questionnaires 
used in previous studies [12, 20, 29]. The questionnaire was reviewed for content and face validity by 
two expert consultants, who previously provided support to PTCs and had considerable experience 
with, and knowledge of, the functioning of PTCs. Following this expert review, the questionnaire was 
modified, with additional questions added, to enhance its robustness.  
 
The questionnaire included close-ended, open-ended, Likert scale and rating scale questions. Data 
were collected over a period of four months in 2017. After the pharmacist was contacted 
telephonically, he/she was emailed an invitation with a link to access and respond to the 
questionnaire online. Supporting documents, providing information about the study, ethical clearance 
and permission from authorities, were attached to the invitation. All participants were reminded about 
the survey vial email, with a request for those who had already completed the questionnaire to ignore 
the reminders.  This methodology was undertaken because SurveyMonkey® does not keep a record 
of email addresses from which completed questionnaires are sent, therefore ensuring anonymity. An 
initial reminder was sent after a month, followed by 2-weekly reminders in the second month and 
weekly reminders in the last two months (17 reminders in total), after which the survey closed. 
 
An online electronic survey was regarded the most appropriate method to distribute the questionnaire 
and collect the data, considering i) the size of the country; ii) the study being conducted in all nine 
provinces; and iii) lack of available manpower and finances to travel and administer the questionnaire 
using face-to-face interviews. Advantages of web-based questionnaires are that they can speed-up 
the process, reach as many potential interviewees as possible as well as remove some of the 
bottlenecks associated with more traditional approaches [30, 31], however, recognizing that response 
rates may not be as high as with paper-based surveys [32]. 
 
2.4 Data analysis 
Data were exported from SurveyMonkey® to Microsoft Office Excel™, cleaned, coded and then 
imported into Statistical Package for the Social Sciences (SPSS) version 24 for analysis. Descriptive 
statistics were used to summarise categorical variables as frequency counts and percentages. Open 
ended responses were manually categorised to allow frequency and percentage calculation. 
 
2.5 Ethical considerations 
Ethical clearance was obtained from Sefako Makgatho University Research Ethics Committee 
(SMUREC/H/171/PG: 2016) and permission to conduct the study was granted by the National and 
Provincial Departments of Health and the management from individual hospitals. The questionnaire 
was completed anonymously and contained a consent statement, stating that completion of the 
questionnaire consequently implied consent. Participation in the study was entirely voluntarily upon 
receiving the link to the survey and the supporting documents.  
 
3. Results  
 
3.1 Response rate  
After four months, 86 of the 268 emailed and delivered questionnaires were returned, which resulted 
in a response rate of 32.1%. Two (0.7%) pharmacists declined participation and 180 (67.2%) did not 
respond.  Table 1 shows a summary of the target population and the study population per province. 
Not all participants responded to all questions in the questionnaire, hence the difference in sample 
size in the presentation of the results. 
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Table 1: Target population, study population and response rate per province 
 
Province 
Target 
populati
on 
(n=412) 
Excluded from target population  Email 
invitatio
n 
delivere
d 
Study population (n=268) 
No 
pharmacy 
No 
PTC 
No email 
address 
obtained 
Undelivered 
Declined 
participatio
n 
Non- 
responses 
Response 
rate 
Eastern Cape 91 1 16 25 1 48 1 (1.1%) 32 (68.1%) 15 (31.9%) 
Free State 32 0 4 6 3 19 0 (0.0%) 14 (73.7%) 5 (26.3%) 
Gauteng 34 0 0 4 2 28 0 (0.0%) 20 (71.4%) 8 (28.6%) 
KwaZulu Natal 72 1 1 13 3 54 1 (1.4%) 33 (62.3%) 20 (37.7%) 
Limpopo 41 0 0 3 1 37 0 (0.0%) 25 (67.6%) 12 (32.4%) 
Mpumalanga 34 0 0 12 0  22 0 (0.0%) 17 (77.3%) 5 (22.7%) 
Northern Cape 22 1 10 7 0 4 0 (0.0%) 4 (100%) 0 (0.0%) 
North West 27 0 1 3 1 22 0 (0.0%) 10 (45.5%) 12 (54.5%) 
Western Cape 59 5 3 17 0 34 0 (0.0%) 26 (76.5%) 8 (13.6%) 
Unspecified* - - - - - - - (-1) 1 
Total number 
(%) 
412 
8  
(1.9%) 
35 
(8.5%
) 
90 
(21.8%) 
11 
(2.7%) 
268 
2 
(0.7%) 
180 
(67.2 %) 
86  
(32.1 %) 
*Participant did not indicate a province; therefore, the total number of non-responses cannot be concluded 
 
3.2 Characteristics of sample population 
Table 2 shows the characteristics of the participating hospitals and the respective pharmacists who 
participated in the survey. Nearly two-thirds (60.5%) of the participating hospitals were district 
hospitals. Bed capacity varied between ≤100 beds (23.4%), 101-200 beds (22.1%), and 201-400 beds 
(27.9%) to more than 400 beds (26.7%). For a third of the respondents (33.7%), the PTC at their 
hospital had been in existence for ≤5 years. 
 
Of the 86 respondents, 55.8% were female. The majority (81.4%) of the pharmacists’ highest 
qualification was a Bachelor of Pharmacy (BPharm) degree, with only 12 (14.0%) having a 
postgraduate qualification. More than half (55.3%) of pharmacists held a managerial cadre position in 
the hospital. Half of the respondents had ≤10 years of experience as a practicing pharmacist and one 
third had served ≤5 years on the PTC at their current hospital. Most participants had between 0-5 
years’ experience in their hospital’s PTC (Table 2).  
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Table 2: Characteristics of participating hospitals and their respective pharmacists (n=86)  
 
Characteristics of participating hospital and pharmacist (n=86) Number (%) 
Hospital level of care District (Level 1) 52 (60.5%) 
 Regional (Level 2) 16 (18.6%) 
 Tertiary (Level 3) 7 (8.1%) 
 National 1 (1.2%) 
 Specialised 10 (11.6%) 
Hospital bed capacity ≤100 20 (23.4%) 
 101-200 19 (22.1%) 
 201-400 24 (27.9%) 
 401-600 5 (5.8%) 
 601-800 4 (4.7%) 
 801-1000 4 (4.7%) 
 >1000 1 (1.2%) 
 Other 9 (10.2%) 
Number of years current PTC in existence ≤5 29 (33.7%) 
 6-10 22 (25.6%) 
 11-15 12 (14.0%) 
 16-20 3 (3.5%) 
 21-25 1 (1.2%) 
 26-30 3 (3.5%) 
 >30 1 (1.2%) 
 Other 15 (17.3%) 
Age (years) ≤30 17 (19.8%) 
 31-40 42 (48.8%) 
 41-50 13 (15.1%) 
 51-60 12 (14.0%) 
 >60 2 (2.3%) 
Professional qualification BPharm 70 (81. %) 
 MPharm 9 (11%) 
 PharmD 2 (2. %) 
 PhD 1 (1. %) 
 No response 4 (5%) 
Years of practice as a pharmacist ≤10 43 (50.0%) 
 11-20 21 (24.4%) 
 21-30 14 (16.3%) 
 31-40 5 (5.8%) 
 >40 1 (1.2%) 
 No response 2 (2.3%) 
Position in hospital Managerial cadre 47 (55.3%) 
 Senior pharmacist 37 (43.5%) 
 Junior pharmacist 1 (1.2%) 
 Other 1 (1.2%) 
Number of years serving on current PTC 0-5 51 (59.3%) 
 6-10 16 (18.6%) 
 11-15 11 (12.8%) 
 16-20 1 (1.2%) 
 21-25 1 (1.2%) 
 Other 6 (6.9%) 
Number of years experience in PTC 0-5 43 (50.0%) 
 6-10 20 (23.3%) 
 11-15 13 (15.1%) 
 16-20 5 (5.8%) 
 21-25 1 (1.2%) 
 Other 4 (4.6%) 
Position in PTC Secretariat 44 (51.2%) 
 Chairperson 17 (19.8%) 
 Member or pharmacy representative 13 (15.1%) 
 Deputy chairperson 2 (2.3%) 
 Chairperson and secretariat 2 (2.3%) 
 Primary health care pharmacist 1 (1.2%) 
 Advisory pharmacist 1 (1.2%) 
6 
Characteristics of participating hospital and pharmacist (n=86) Number (%) 
 Pharmacovigilance and AMS champion 1 (1.2%) 
 Secretariat and AMS chairperson 1 (1.2%) 
AMS: Antimicrobial stewardship 
 
3.3 Structure of PTCs and meetings 
The composition of the PTC included in the majority of cases a medical practitioner (97.6%), 
pharmacist (100%) and a nurse (97.6%). Administrative officers had a 25.6% representation on the 
PTCs. The size of the PTCs reported in the hospitals taking part in the survey, ranged between 11-15 
members in 30.2% of cases, 16-20 in 20.9%, and 21-25 members in 20.9% of cases. Table 3 shows 
that pharmacists’ representation in their hospital PTC was usually as the secretariat (51.2%) and 
among 19.8% of the PTCs the pharmacists were the chairperson.  
 
Table 3: Pharmacist’s position in the hospital PTC 
 
Position in hospital PTC Number (%) (n=86) 
Secretariat 44 (51.2%) 
Chairperson 17 (19.8%) 
Member/pharmacy representative 13 (15.1%) 
Deputy chairperson 2 (2.3%) 
Chairperson and secretariat 2 (2.3%) 
Primary health care pharmacist 1 (1.2%) 
Advisory pharmacist 1 (1.2%) 
Pharmacovigilance and antimicrobial stewardship champion 1 (1.2%) 
Secretariat and antibiotic stewardship chairperson 1 (1.2%) 
 
The number of PTC meetings held annually ranged between four and 12 times a year. PTC meetings 
were typically held either monthly (47.9%) or every quarter (47.9%). The number of PTC members 
required for a quorum ranged between 6-10 members (37.2%) and 11-15 members (14%).In 37.2% of 
hospitals, 5-10 members would typically attend the PTC meetings, followed by 11-15 members in 
32.6% of the hospitals.  
 
According to the respondents, a quorum was met in the majority of PTC meetings, either always 
(37.5%) or often (41.3%). Four (5.0%) respondents indicated that they did not know how often their 
PTC meeting reached a quorum. 
 
3.4 Functions and responsibilities of PTCs 
The primary functions of the PTC in most hospitals (86,0%) as presented in Table 4 were ensuring 
the rational use of medicines, specifically medicine use evaluation and medicine use review. This was 
the case at all levels of care, with 100% of the tertiary hospital and 90.0% of the specialised hospital 
respondents confirming this function. Pharmacovigilance, with reference to the management of ADRs, 
handling of product complaints and medication errors was also common (82.6%), as was 
implementing STGs (77.9%). Overall 72.1% of hospital PTCs had antimicrobial stewardship (AMS) 
programmes in place with specialized hospitals and district hospitals being the lowest, with two thirds 
(60.0% and 67.3% respectively) reporting that they have AMS programmes.   
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Table 4: Functions of the PTC  
 
Function 
District 
(n=52) 
Regional 
(n=16) 
Tertiary 
(n=7) 
Central 
(n=1) 
Specialised 
(n=10) 
Total 
(n=86) 
Rational medicine use (Medicine 
use evaluation; medicine use 
review) 
4 (82.7%) 14 (87.5%) 7 (100.0%) 1 (100%) 9 (90.0%) 7 (86.0%) 
Pharmacovigilance (Management 
of adverse drug reactions; product 
complaints; medication errors) 
41 (78.8%) 14 (87.5%) 6 (85.7%) 1 (100%) 9 (90.0%) 71 (82.6%) 
Implementing Standard Treatment 
Guidelines 
43 (82.7%) 12 (75.0%) 5 (71.4%) 1 (100%) 6 (60.0%) 67 (77.9%) 
Antibiotic stewardship 35 (67.3%) 13 (81.3%) 7 (100.0%) 1 (100%) 6 (60.0%) 62 (72.1%) 
Prepare and monitor a budget for 
medicines 
30 (57.7%) 9 (56.3%) 4 (57.1%) 1 (100%) 5 (50.0%) 49 (57.0%) 
Develop and maintain medicines 
formularies 
24 (46.2%) 12 (75.0%) 5 (71.4%) 1 (100%) 4 (40.0%) 46 (53.5%) 
Monitoring and reporting on 
above; Enforce compliance to the 
Good Pharmacy Practice and 
legal requirements 
 
 
 
 
1 (14.3%) 
 
 
 
 
1 (1.2%) 
New drugs needed; adverse drug 
reactions; prescriber levels 
 
 
1 (6.3%) 
 
 
 
 
 
 
1 (1.2%) 
Antibiotic stewardship is a 
separate committee 
 
 
1 (6.3%) 
 
 
 
 
 
 
1 (1.2%) 
Inform of pharmacy stock outs 
and alternative treatment 1 (1.9%)     1 (1.2%) 
ABC and VEN analysis; blood and 
blood products 1 (1.9%)     1 (1.2%) 
 
3.5 Monitoring of PTC performance 
Of the 86 respondents, 80 completed this section of the questionnaire. Only 37.5% of respondents 
stated that they were using monitoring and evaluation indicators to monitor the PTC performance.  
The most common reasons for not using indicators are provided in Table 5 and include people not 
being aware of indicators (66.0%), which was the case for all respondents from the regional- and 
specialized hospitals. Another reason cited by 36.2% of hospitals, was lack of time (Table 5). 
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Table 5: Availability of and the use of performance indicators by PTCs 
 
Hospital level of care 
District 
(n=28) 
Regional 
(n=15) 
Tertiary 
(n=7) 
Central 
(n=1) 
Specialise
d (n=10) 
Total 
(n=80) 
Monitoring and evaluation 
indicators are used to 
monitor performance 
15 
(31.3%) 
7 (46.7%) 3 (42.9%) 
1 
(100.0%) 
4 (44.4%) 
30 
(37.5%) 
Barriers preventing the use of monitoring and evaluation PTC indicators  
Not aware of indicators 
18 
(54.5%) 
8 
(100.0%) 
2 (50.0%) NA 5 100.0% 
33 
(66.0%) 
Lack of time 
12 
(36.4%) 
2 (25.0%) 1 (25.0%) NA 1 (20.0%) 
16 
(32.0%) 
Lack of resources 
10 
(30.3%) 
1 (12.5%) 1 (25.0%) NA 1 (20.0%) 
12 
(24.0%) 
Lack of pharmacy staff 8 (24.2%) 2 (25.0%) 0 (0.0%) NA 0 (0.0%) 
10 
(20.0%) 
Other 6 (18.2%) 1 (12.5%) 1 (25.0%) NA 0 (0.0%) 8 (16.0%) 
Indicators too difficult to 
understand 
2 (6.1%) 0 (0.0%) 1 (25.0%) NA 0 (0.0%) 3 (6.0%) 
Categories of indicators being used 
Input indicators 
8 (53.3%) 5 (71.4%) 1 (33.3%) 
1 
(100.0%) 
2 (50.0%) 
17 
(56.7%) 
Process indicators 
7 (46.7%) 34 (2.9%) 1 (33.3%) 0.0% 0.0% 
11 
(36.7%) 
Output indicators 
6 (40.0%) 4 (57.1%) 2 (66.7%) 0.0% 2 (50.0%) 
14 
(46.7%) 
Outcome indicators 10 
(66.7%) 
3 (42.9%) 2 (66.7%) 0.0% 3 (75.0%) 
18 
(60.0%) 
Impact indicators 
8 (53.3%) 4 (57.1%) 0.0% 
1 
(100.0%) 
2 (50.0%) 
15 
(50.0%) 
Section 21 item 0.0% 1 (14.3%) 0.0% 0.0% 0.0% 1 (3.3%) 
 
Hospital level of care 
District 
(n=24) 
Regional 
(n=8) 
Tertiary 
(n=3) 
Central 
(n=1) 
Specialise
d (n=6) 
Total 
(n=42) 
Use of indicators 
Feedback to the PTC 21 
(87.5%) 
6 (75.0%) 3 (100.0%) 
1 
(100.0%) 
4 (66.7%) 
35 
(83.3%) 
Informed decision making 14 
(58.3%) 
3 (37.5%) 100.0% 0.0% 4 (66.7%) 
24 
(57.1%) 
Feedback to hospital or 
area health services 
13 
(54.2%) 
4 (50.0%) 1 (33.3%) 
(1) 
100.0% 
3 (50.0%) 
22 
(52.4%) 
Feedback to Heads of 
Departments 
11 
(45.8%) 
4 (50.0%) 2 (66.7%) 
1 
(100.0%) 
1 (16.7%) 
19 
(45.2%) 
Monitoring and Evaluation 
of PTC performance 
11 
(45.8%) 
2 (25.0%) 1 (33.3%) 0.0% (2) 33.3% 
16 
(38.1%) 
Accreditation (COHSASA) 
2 (8.3%) 0.0% 0.0% 
1 
(100.0%) 
0.0% 3 (7.1%) 
Other (please specify) 0.0% 1 (12.5%) 0.0% 0.0% 1 (16.7%) 2 (4.8%) 
*More than one response option allowed 
 
The three types of indicators mostly used among the PTCs were outcome indicators (60. 0%), input 
indicators (56.7 %) and impact indicators (50.0%). Examples of indicators used in the surveyed 
hospitals included the following: 
 Number of PTC meetings held which a quorum of members was present, per annum (output  
 indicator), percentage of PTC members who attend at least 75% of meetings per annum (process  
 indicator) and medicine expenditure per capita/patient (outcome indicator)  
 Number of ADR reports submitted with interventions (output indicator) 
 Evaluation of prescriptions for clarity and adherence to prescription standards (outcome  
 indicators) 
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The pharmacist (79.1%) and secretary (53.5%) of the PTC were identified as the individuals who 
would collect PTC indicator data. Other members of the PTC who collected data were quality 
assurance officers (2.3%) and primary healthcare nurses (1.2%). The most common reason for 
collecting PTC indicator data was to provide feedback to the PTC (83.3%). Other reasons are shown 
in Table 5. 
 
3.6 Implementation of PTC decisions 
Nearly two thirds of the participants (62.0%) mentioned that guidelines on implementing PTC 
decisions did not exist in their hospital. However, the vast majority (95.1%) of the respondents stated 
that the decisions of the PTC at their hospital were implemented, typically monthly (40.3%) or 
quarterly (40.3%). Others responded that they implement decisions as required/needed/deemed 
necessary, as soon as possible, if a decision was agreed upon, every second month, and as 
decisions were made/taken (Table 6).  
 
Table 6: Implementation of PTC decisions 
 
Hospital level of care District Regional Tertiary Central 
Specialis
ed 
Total 
n 48 16 7 1 9 81 
PTC decisions are 
implemented 
47 
(97.9%) 
13 
(81.3%) 
7 
(100.0%) 
1 
(100.0%) 
9 
(100.0%) 
77 
(95.1%) 
  
n 46 16 7 1 9 79 
Guidelines exist on 
implementing PTC 
decisions 
17 
(37.0%) 
6 (37.5%) 
4 
(57.1%) 
1 
(100.0%
) 
2 
(22.2%) 
30 
(38.0%) 
  
n  41 12 3 1 5 62 
Frequency 
of PTC 
decision 
implementati
on 
Monthly 
17 
(41.5%) 
4 (33.3%) 
1 
(33.3%) 
1 
(100.0%
) 
2 
(40.0%) 
25 
(40.3%) 
Quarterly 16 
(39.0%) 
4 (33.3%) 
2 
(66.7%) 
0.0% 
3 
(60.0%) 
25 
(40.3%) 
Twice a year 2 (4.9%) 1 (8.3%) 0.0% 0.0% 0.0% 3 (4.8%) 
Once a year 5 
(12.2%) 
1 (8.3%) 0.0% 0.0% 0.0% 6 (9.7%) 
Never 1 (2.4%) 2 (16.7%) 0.0% 0.0% 0.0% 3 (4.8%) 
 
n 48 15 7 1 9 80 
Factors 
considered 
important 
when 
implementin
g PTC 
decisions 
Patient 
safety 
46 
(95.8%) 
15 
(100.0%) 
7 
(100.0%
) 
1 
(100.0%
) 
8 
(88.9%) 
77 
(96.3%) 
Cost 
40 
(83.3%) 
13 
(86.7%) 
7 
(100.0%
) 
1 
(100.0%
) 
8 
(88.9%) 
69 
(86.3%) 
Significance 
35 
(72.9%) 
12 
(80.0%) 
7 
(100.0%
) 
1 
(100.0%
) 
5 
(55.6%) 
60 
(75.0%) 
Urgency of 
matter 
30 
(62.5%) 
14 
(93.3%) 
6 
(85.7%) 
1 
(100.0%
) 
8 
(88.9%) 
59 
(73.8%) 
Other 1 (2.1%) 0.0% 
1 
(14.3%) 
0.0% 
1 
(11.1%) 
1 (1.3%) 
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The reasons given by four (4.9%) hospitals who indicated that PTC decisions were not being 
implemented in their hospital were the following: 
 Negativity of medical practitioners as they perceive PTCs to be time consuming 
 PTC decisions are not taken to the hospital management by the chairperson 
 Lack of interest 
 
When implementing PTC decisions, patient safety (96.3%), cost (86.3%), significance (75.0%) and 
urgency of the matter (73.8%) were regarded as important. Other reasons considered as important 
were clinical evidence, efficacy of medicines and availability of medicines (Table ??).  
 
3.7 Evaluation and review of outcomes of PTC decisions 
Two-thirds (65.4%) of pharmacists indicated that PTC decisions were evaluated in their hospitals, with 
the majority stating either ‘often’ (44.6%) or ‘always’ (33.9%). The reasons why decisions were not 
evaluated in the remainder of hospitals included lack of time, not having an active monitoring and 
evaluation programme, lack of interest and nobody to evaluate decisions taken. In the majority of 
hospitals (83.8%), PTC decisions were reviewed. Reasons for decisions not being reviewed included 
lack of time, not receiving feedback, believing that not all decisions needed review and lack of 
interest. 
 
Half (49.3%) of the responding pharmacists stated that the PTC decisions were ‘often’  reviewed and 
indicated that the purposes of evaluating and reviewing decisions are to monitor/measure the 
effectiveness of decisions taken, to monitor progress and implementation, and to ensure that 
decisions taken are practical, and if not, revise the decision. 
 
3.8 Dissemination of PTC decisions 
Figure 1 shows the different methods used by PTCs to disseminate their decisions. An email (59.5%) 
was the primary means of communicating decisions, followed by personal communication (53.2%). 
Other ways of communication stated were the use of minutes (7.0%) and WhatsApp messages 
(2.3%).  
 
Figure 1: Methods of dissemination of PTC decisions (n=79) 
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4. Discussion 
 
The overall response rate was 32.3% (86 of 279 hospitals) despite 17 reminders being sent out. This 
was much lower than the study conducted in Denmark with a 100% response rate, however, only nine 
hospitals were targeted [33]. Our response rate was similar to that of a survey among physicians in 
Malaysia (34.8%) [34], and higher though than seen among physicians taking part in web based 
survey in Sweden (28%) [31] and a Canadian study where the response rate was only 24% [20]. This 
may be a reflection of the large number of targeted hospitals in our survey. 
 
Encouragingly, membership of PTCs  in this study was in line with PTC guidelines [1], as well as the 
South African policy on PTCs which specifies that membership should include a range of expertise 
and skills to reflect its scope and functions [17]. Although not reported in our results, some PTCs 
included quality assurance officers, pharmacist assistants, clinical assistants and hospital Chief 
Executive Officers. The majority of pharmacists held the position of a secretary in their hospital PTCs, 
similar to other studies [12, 35, 36]. However, only pharmacists were invited to participate in the 
survey; consequently, pharmacists were represented in all PTCs taking part. Having said this, medical 
practitioners and nurses still had a high representation (97.6%) in PTCs throughout public sector 
hospitals in the provinces in South Africa. Our findings though contrast with studies conducted in 
Canada, Denmark and Thailand, where physicians comprised the majority of PTC members. While 
pharmacists and nurses had approximately equal representation in Canada [20], most PTC members 
were specialist physicians (48%), pharmacists (12%), general practitioners (8%) and nurses (7%) in 
Denmark; and, in Thailand, the majority of PTC members were physicians with an average of two 
pharmacists and one nurse [33, 36]. 
 
Our study results show that PTCs met on average 8 times a year (range 4-12), which is in line with 
WHO standards, similar to our earlier study [12]. This is also similar to Canada where PTCs met on 
average 6.2 times per year [20] but higher than Denmark and Pakistan where PTCs meet on average 
four times a year [33,35].  
 
The number of members in the PTCs ranged between 11-15 members (30.2%) or higher (41.8%), 
similar to Thailand where PTCs consisted of 13-32 members [36]. This was also comparable or higher 
than Canada (11 members) [20] and Australia, where the number of PTC members ranged from 2-16 
[28]. The number of PTC members in our study required to form a quorum were between 6-10 
members, which encouragingly was often met.   
 
The main functions of the PTCs in our study were RMU, pharmacovigilance and Implementing STGs 
(Table 4). The goal of implementing STGs (81.7% of respondents) is encouraging as implementing 
STGs enhances the quality of prescribing, with targets of 90% in some countries [37, 38]. Our findings 
though differ from Canada where the principal functions of PTCs included ADR monitoring (83%), 
drug-use making policy (92%) and drug use monitoring (80%) [20]. In Denmark, the main 
responsibilities and activities of the PTCs were to develop hospital drug formularies, and policies and 
guidelines [33], and in Thailand, the functions of the PTCs were drug evaluation and selection of 
medicines for the hospital formulary as well as development of drug policies [36]. However, they can 
potentially be seen as similar in that they all focus on medicine policies and pharmacovigilance, which 
are two important aspects of the PTC functions to ensure RMU. 
 
Continuous self-monitoring of performance using indicators has been shown to improve PTC 
performance [36], with Vang et al. [22] suggesting that the indicators can be collected by the PTC 
members themselves as a means of carrying out an assessment of their performance in relation to 
identified tasks (standards). Whilst outcome indicators, input indicators, and output indicators were 
used in some of the surveyed hospitals to monitor PTC performance, principally to give feedback to 
PTCs (Table 5), with the pharmacist and secretary in the PTCs identified as key individuals collecting 
PTC indicator data, disappointingly, 63.8% of the surveyed PTCs were not using indicators to monitor 
PTC performance. The principal reasons for not using indicators were a lack of awareness and time 
(Table 6). This is a concern and will be addressed in future studies and activities as we are unaware 
of any previous study conducted in South Africa on the use of performance indicators among PTCs. 
 
Considerable efforts were made to implement the decisions from the PTCs (95.1%) despite the lack 
of guidelines on implementing PTC decisions in most of the PTCs surveyed. Furthermore, it could not 
be determined from the study which guidelines were used by the PTCs to implement their decisions. 
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This was in direct contrast to a study in Denmark where little effort was made to implement PTC 
decisions [33]. Barriers to implementing PTC decisions included the negativity of medical practitioners 
as they perceived PTCs as time consuming, which needs to be addressed to improve future medicine 
management. This is different though from other studies where inadequate PTC structures and 
organizations were considered barriers to implementing decisions [39].  
 
Suggestion to address barriers of time and importance (Table 5) include assigning a greater priority to 
PTC decisions, and that decisions which are assigned a high priority should be implemented first [29]. 
Greater education among pharmacy students, resident pharmacists, and others around PTC 
indicators is also recommended, and will be implemented, to address concerns with lack of 
knowledge and understanding. Lack of pharmacy staff can potentially be overcome through greater 
use of technology especially as for instance national guidelines are now readily available and updated 
via mobile apps [18]. 
 
In our study, patient safety, urgency, significance and cost were also considered of importance in PTC 
decision making, although patient safety was chosen as the most important. This is similar to other 
studies that reported that all respondents indicated “patient safety” as a key domain for a PTC 
decision and nearly one third of the respondents considered “urgency as a characteristic of decision 
that could grant a significant importance rating” [29, 40]. Other domains which conferred importance 
upon PTC decisions, included those dealing with “cost” (93%) similar to other studies [29, 40]. 
 
As mentioned, a key concern in our study was the lack of time and interest in following up PTC 
decisions in a number of the hospitals. Encouragingly though, respondents recognized the importance 
of evaluating and reviewing PTC decisions, and some respondents even specified that the rationale of 
PTCs is to monitor the effectiveness and impact of decisions taken. Encouragingly as well is that the 
majority of respondents in our study stated that PTC decisions are in fact regularly evaluated and 
subsequently reviewed in their hospital. Evaluation of decisions enhances PTC accountability and 
ensures credibility of decisions taken, thereby enhancing RMU in the hospital. Other concerns 
included the fact that 1.9% of hospitals initially surveyed had no pharmacists and 8.5% had no PTC 
(Table 1). This again needs to be addressed to meet national guidelines. 
 
In our study, emails were the primary means of communication to disseminate PTC information. 
Personal communication was another preferred form of communication. This is different to other 
studies that found that PTC decisions were principally communicated via printed material (80%), 
although targeted emails were also frequently used (61%) [20]. This though may well have changed in 
recent years. 
 
We acknowledge that our response rate could raise questions about the representativeness of our 
data. We are also aware that we only targeted pharmacists for the survey. Another concern is that 90 
hospitals could not be reached for requisitions of their email addresses due to calls not going through 
and pharmacists forming part of the PTC not being available during the time of study. Despite these 
limitations, we believe the findings are robust and provide good background information for future 
research and interventions.  
 
4. Conclusion  
 
Encouragingly a high number of respondents stated that the principal activities of PTCs centered 
around the rational use of medicines as well as seek to implement STGs, providing guidance to 
hospitals in other lower and middle income countries (LMICs) seeking to enhance the activities of 
PTCs to address concerns with the rational use of medicines in their countries. However, it was 
evident from our study that guidelines on implementing PTC decisions are lacking in public sector 
hospitals in South Africa. This needs to be addressed to enhance the effectiveness of PCTs in South 
Africa building on national endorsement for all hospitals to have PTCs. Such guidelines will also be 
useful to other LMICs as they seek to enhance PTC activities. 
 
Whilst most decisions taken in the PTC meetings in the public hospitals in South Africa were 
implemented, there were typically no formal guidelines of implementing PTC decisions within the 
hospitals. This is another important area to address in the future among public sector hospitals as the 
implementation of decisions without the use of guidelines could lead to loss of accountability by PTC 
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members in the long term as well as loss of information, with both potentially detrimental to the health 
of the patients. Again, such guidance will also be useful to other LMICs. 
 
There are also concerns that PTCs were not routinely monitoring their performance using recognized 
indicators, implying that public sector hospitals in South Africa do not routinely submit PTC indicator 
reports as per recognized guidelines [12].  This is also an important area to address in South Africa 
and wider, and will be the subject of future research, as not monitoring PTC decisions also indicates 
that the PTC’s functionality is not being routinely measured and therefore their effectiveness cannot 
be fully realized or determined. Nevertheless, decisions taken in these PTCs are said to be evaluated 
and subsequently reviewed, and we will be following this up in future research. All these gaps and 
challenges create room for future implementation of guidelines in all South African public sector 
hospital PTCs, which will guide PTCs from selecting PTC members to implementing and 
dissemination of PTC decisions. PTC guidelines could also be adopted from other countries that have 
guidelines that have strengthened their PTCs.  
 
Overall, the results of the study can guide future amendments of hospital PTC guidelines, which is  
starting to happen.  
 
5. Key Issues 
 
The National Drug Policy in South Africa has strengthened PTCs through directives and guidelines. 
However, little is known about the implementation of such policies.  
 
Typically, membership of PTCs in public hospitals in South Africa included pharmacists, which 
generally were the secretary. Principal activities of PTCs included encouraging the rational use of 
medicines as well as implementing STGs and pharmacovigilance activities (81% to 90% of hospitals 
surveyed for these functions). The vast majority of hospitals (95.1%) currently implement PTC 
decisions; however, there was typically, a lack of guidelines on how to implement such decisions In 
addition, there was a lack of using indicators to monitor PTC activities and provide feedback. These 
concerns are being addressed  
 
6. Expert Commentary 
 
The National Drug Policy in South Africa sought to strengthen Pharmacy and Therapeutics 
Committees (PTCs) activities among public and private hospitals. Typically, membership of PTCs 
among public hospitals currently include a pharmacist, who generally hold a secretariat position. 
Encouragingly, the principal activities of PTCs among public hospitals include encouraging the 
rational use of medicines (RUM) (90.2%), implementing standard treatment guidelines (STGs) 
(81.7%) as well as undertaking pharmacovigilance (86.6%) activities. 
 
Whilst most decisions taken in the PTC meetings in the public hospitals are being implemented 
(95.1% of hospitals), there are currently typically no formal guidelines for implementing such 
decisions. In addition, whilst most PTC decisions are being evaluated and reviewed, 63.8% of public 
hospitals are currently not using recognized indicators to monitor PTC performance. This is probably 
due to the lack of awareness of PTC indicators by the respondents., These are important area to 
address in the future to improve RMU within public hospitals in South Africa, which is starting to 
happen.  
 
7. Five-year review 
 
We would expect to see the principal activities of PTCs including encouraging RMU, implementation 
of STGs and undertaking pharmacovigilance activities to be routine within all public hospitals in South 
Africa. We would also expect PTC activities to be implemented and monitored, helped by the 
introduction of formal guidelines in all public hospitals. We would also expect all PTCs in public 
hospitals to be using recognized indicators to monitor their performance to further encourage RMU. 
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